argenx NV ADR
$ 840.28
1.70%
24 Feb - close price
- Market Cap 51,131,167,000 USD
- Current Price $ 840.28
- High / Low $ 842.09 / 827.83
- Stock P/E 35.34
- Book Value 99.66
- EPS 23.38
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.25 %
- 52 Week High 934.62
- 52 Week Low 510.06
About
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Analyst Target Price
$1028.20
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-30 | 2025-07-15 | 2025-05-07 | 2025-02-27 | 2024-10-31 | 2024-07-25 | 2024-05-09 | 2024-02-29 | 2023-10-31 | 2023-07-27 | 2023-05-07 | 2023-03-02 |
| Reported EPS | 5.18 | 3.2572 | 2.2732 | 0.7125 | 1.39 | 0.45 | -1.04 | -1.68 | -1.25 | -1.69 | -0.71 | -0.7 |
| Estimated EPS | 4.44 | -0.99 | 2.0546 | 1.6979 | 0.03 | -0.98 | -0.86 | -1.7 | -1.54 | -1.73 | -2.26 | -0.7 |
| Surprise | 0.74 | 4.2472 | 0.2186 | -0.9854 | 1.36 | 1.43 | -0.18 | 0.02 | 0.29 | 0.04 | 1.55 | 0 |
| Surprise Percentage | 16.6667% | 429.0101% | 10.6395% | -58.0364% | 4533.3333% | 145.9184% | -20.9302% | 1.1765% | 18.8312% | 2.3121% | 68.5841% | 0% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 6.2 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ARGX
2026-02-23 06:00:33
argenx, a global immunology company, announced that COO Karen Massey will participate in a fireside chat at the TD Cowen 46th Annual Healthcare Conference on March 2. A live webcast and replay of her presentation will be available on the Investors section of the company's website. The company is dedicated to improving the lives of people with severe autoimmune diseases and develops novel antibody-based medicines.
2026-02-23 05:57:37
argenx SE announced that its Chief Operating Officer, Karen Massey, will participate in a fireside chat at the TD Cowen 46th Annual Healthcare Conference on Monday, March 2, at 11:50 a.m. ET. A live webcast of the presentation will be available on the Investors section of the argenx website, with a replay accessible for approximately 30 days afterward. argenx is a global immunology company focused on developing antibody-based medicines for severe autoimmune diseases.
2026-02-19 08:49:49
argenx, a global immunology company, announced it will host a conference call and audio webcast on February 26, 2026, to discuss its full year 2025 financial results and provide a fourth-quarter business update. The event will be accessible via its website, and replay will be available for approximately one year. Dial-in numbers and an access code are provided for participants.
2026-02-06 08:33:00
Baron Health Care Fund's Q4 2025 investor letter highlighted Argenx SE (NASDAQ:ARGX) as a key contributor to its performance, largely due to stronger-than-expected sales of its drug Vyvgart. The biopharma company's shares gained 26.86% over the last 52 weeks, driven by successful launches in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, with anticipated efficacy in more autoimmune conditions. The fund remains optimistic about Vyvgart's long-term growth potential and Argenx's pipeline.
2026-02-01 10:28:10
Argenx SE – ADR (NASDAQ: ARGX) saw its market sentiment boosted after the FDA accepted priority review for a supplemental biologics license application for the immune disorder drug Vyvgart, aimed at expanding its use for adults with acetylcholine receptor antibody-seronegative generalized myasthenia gravis (gMG). This priority review is expected to accelerate regulatory decisions. Analysts like William Blair reiterated Outperform ratings, citing strong sales momentum for the Vyvgart franchise and confidence in other clinical assets.
2026-01-30 08:00:30
Argenx's Vyvgart sales are exceeding expectations for myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP) treatments, with strong momentum projected through 2026. William Blair maintained an Outperform rating on Argenx SE (ARGX), highlighting Vyvgart's performance and the potential of other clinical products like empasiprubart. The FDA has also granted priority review for a supplemental biologics licensing application to expand Vyvgart's use in generalized myasthenia gravis.
